

Angioimmunoblastic T cell lymphoma: novel molecular insights by mutation profiling

Ming Wang^{1,*}, Shaowei Zhang^{2,1,*}, Shih-Sung Chuang³, Margaret Ashton-Key⁴, Eguzkine Ochoa¹, Niccolo Bolli^{5,6,7}, George Vassiliou⁵, Zifen Gao², Ming-Qing Du¹

¹Division of Molecular Histopathology, Department of Pathology, University of Cambridge, Cambridge, UK

²Department of Pathology, Health Science Centre, Peking University, Beijing, China

³Department of Pathology, Chi-Mei Medical Center, Tainan, Taiwan

⁴Department of Cellular Pathology, Southampton University Hospitals National Health Service Foundation Trust, Southampton, UK

⁵Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, UK

⁶Department of Oncology and Onco-Hematology, University of Milan, Milan, Italy

⁷Department of Hematology and Pediatric Onco-Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

*These authors contributed equally to this work

Correspondence to: Ming-Qing Du, **email:** mqd20@cam.ac.uk
Zifen Gao, **email:** wjshgao@bjmu.edu.cn

Keywords: AITL, WES, somatic mutation, oncogenic mechanism

Received: March 22, 2016

Accepted: January 19, 2017

Published: January 27, 2017

ABSTRACT

Angioimmunoblastic T cell lymphoma (AITL) originates from follicular helper T-cells and is characterised by a polymorphic infiltrate with the neoplastic T-cells forming small clusters around the follicle and high endothelial venules. Despite the recent advances in its phenotypic characterisation, the genetics and molecular mechanisms underlying AITL are not fully understood. In the present study, we performed whole exome sequencing in 9 cases of AITL from Taiwan ($n = 6$) and U.K. ($n = 3$). We confirmed frequent mutations in *TET2* (9/9), *DNMT3A* (3/9), *IDH2* (3/9), *RHOA* (3/9) and *PLCG1* (2/9) as recently reported by others. More importantly, we identified mutations in *TNFRSF21* (1/9), *CCND3* (1/9) and *SAMSN1* (1/9), which are not yet seen or strongly implicated in the pathogenesis of AITL. Among the pathogenic mutations identified in AITL, mutations in DNA methylation regulators *TET2* and *DNMT3A* occur early in hematopoietic stem cells as shown by previous studies, and these genetic events enhance the self-renewal of hematopoietic stem cells, but are unlikely to have any major impact on T-cell differentiation. Mutations in *RHOA*, *PLCG1* and *TNFRSF21* (DR6), which encode proteins critical for T-cell biology, most likely promote T-cell differentiation and malignant transformation, consequently generating the malignant phenotype. Our findings extend the molecular insights into the multistage development of AITL.

INTRODUCTION

Angioimmunoblastic T-cell lymphoma (AITL) is a common subtype of peripheral T-cell lymphoma (PTCL). The vast majority of AITL are associated with EBV infection, however, the neoplastic T-cells are EBV negative. Histologically, AITL is characterized by a polymorphic infiltrate with the neoplastic T-cells typically expanding within a background of prominent arborizing

high endothelial venules and perivascular proliferation of follicular dendritic cells. The polymorphic infiltrate comprises small reactive lymphocytes, B-immunoblasts (often positive for EBV), plasma cells, eosinophils and macrophages.

AITL originates from follicular helper T-cells and the neoplastic T-cells express all the cardinal features of follicular helper T-cells, including CXCR5, CXCL13, ICOS, PD-1, BCL6, SAP and c-MAF, and preserve at

least the major function of follicular helper T-cells, for example, help for antibody production by B-cells [1, 2]. A high-affinity TCR is a characteristic feature of follicular helper T-cells, and is essential for the commitment of CD4+ T cells to differentiate into follicular helper T-cells and also critical for their maintenance and survival. In view of these, TCR signaling may play a critical role in the pathogenesis of AITL.

The genetics of AITL is beginning to unfold. *t(5;9)* (q33;q22)/ITK-SYK, originally identified in the follicular variant of PTCL, has been also found in AITL albeit rather infrequent [3–5]. The ITK-SYK fusion product associates constitutively with lipid rafts in T-cells and triggers antigen-independent phosphorylation of TCR-proximal proteins and activation of their downstream pathways [6, 7]. More recent studies by whole exome sequencing (WES) and targeted sequencing have identified a wide spectrum of somatic mutations in AITL and among those, mutations in *TET2*, *DNMT3A*, *IDH2*, *RHOA* and *CD28* are the most frequent [8–15]. Nonetheless, the number of AITL cases investigated by whole exome sequencing in each of the above studies is small (≤ 5) and the full spectrum of the mutation profile of AITL most likely remains incompletely characterized. In this study, we report the exome mutation profile of 9 well-characterized AITL with emphasis on the novel mutations identified.

RESULTS AND DISCUSSION

Overview of discoveries by WES

WES generated an average of 25.7 million reads per sample, with an average of 89% of the target sequences

being covered by > 10 reads (Supplementary Table 1). As a sufficient amount of matched germline DNA for WES was available only in one case, we performed extensive data filtering to remove the known SNPs reported in databases including the 1000 genome project that contains variants from various ethnic populations including Han Chinese. We also removed the variants that were predicted to lack functional impact by 3 of the 7 mutation functional prediction programs. Consequently, a total of 603 variants in 527 genes were detected in 9 AITL (average 67/case; range 10–90/case) (Supplementary Figure 1). Nonetheless, the number of variants in cases 2–9 was most likely overestimated due to a lack of corresponding germline DNA for WES.

To examine whether this study identified any novel mutations, we compared our data with those of the recent studies by WES and targeted sequencing [8–11]. To our surprise, there was little overlap in the mutation landscape among these different studies despite finding of mutations in a small common set of genes (Figure 1), suggesting genetic heterogeneity in AITL and incomplete mutation discoveries in each of these studies. In addition, the small number of cases investigated, variability in tumor cell content, sequence coverage and efficacy of variant calling most likely contributed to the discrepancy among these different studies. Among a total of 527 mutated genes identified in this study, only 11 were found to be mutated in AITL by previous WES studies.

Pathogenic mutations identified by WES

We confirmed frequent mutations of *TET2* (9/9 cases), *DNMT3A* (3/9), *IDH2* (3/9 cases) and *RHOA*




Figure 1: Number of common and unique genes that are found to harbour mutations by different whole exome sequencing studies [8–10]. In general, there is little overlap among the mutated genes identified by the 4 different studies. The 11 overlap genes with other studies are listed and those known pathogenic are highlighted in red.

(3/9 cases) in AITL (Figures 2 and 3, Supplementary Table 2), which were identified by previous WES and targeted sequencing [8–11]. In line with previous studies, *TET2* mutations were frequently multiple, with 2 mutations seen in 6 cases. The vast majority (14/15 = 93%) of *TET2* mutations were frameshift or nonsense changes, and rather widely distributed without any clusters, suggesting that these mutations were inactivating events. *DNMT3A* mutation was found in three cases, with 2 of the 3

mutations being frameshift or nonsense changes. *DNMT3A* mutation was found exclusively in cases with double *TET2* mutations. *IDH2* mutation affected the same codon although resulting in different substitutions in each of the 3 cases involved, while *RHOA* mutation was exclusively G17V change in all 3 cases involved.

In addition to the above well-established mutations in AITL, we also identified mutations in several genes not yet seen or strongly implicated in the pathogenesis




Figure 2: Nature and distribution of mutations in *TET2*, *DNMT3A*, *IDH2*, *RHOA*, *PLCG1*, *TNFRSF21*, *CCND3* and *SAMSNI*. The vast majority (14/15 = 93%) of *TET2* mutations were frameshift or nonsense changes without any clusters. *DNMT3A* mutation was found in three cases, with 2 of the 3 mutations being frameshift or nonsense changes. Mutation in *IDH2*, *RHOA* and *PLCG1* are exclusively missense changes, while those in *TNFRSF21*, *CCND3* and *SAMSNI* are deleterious alterations.

of AITL and they included *PLCG1*, *TNFRSF21*, *CCND3* and *SAMSN1* (Figures 2 and 3, Supplementary Table 2). All the variants identified by WES and included in the Supplementary Table 2 were confirmed by Sanger sequencing.

PLCG1 was mutated in 2 of the 9 cases of AITL investigated by WES, and both mutations were missense changes, with *PLCG1* S345F reported previously in cutaneous T-cell lymphoma and nodal peripheral T-cell lymphoma [16, 17], and *PLCG1* G869E as a novel change. *PLCG1* S345F, localized in the N-terminal part of the “split” PH domain, was an activating change, enhancing the ability of PLCγ1 to activate NFAT, a transcriptional factor critical for T-cell activation and function [16]. *PLCG1* G869E is in the SH3 domain of the regulatory region, which along with the CSH2 domain, forms an interface with the CSH2-SH3 linker, serving as an auto-inhibitory interaction [18, 19]. *PLCG1* G869E, like R707Q in the CSH2 domain, may cause conformational changes, abolish such auto-inhibitory interaction, and thus activate PLCγ1 [20]. While revision of our manuscript, recurrent *PLCG1* mutations including S345F and G869E have also been reported in AITL by Vallois and colleagues, and most *PLCG1* mutations including S345F and G869E are gain of functional changes as shown by their ability to activate MALT1 and NFAT *in vitro* [21]. PLCγ1 plays an essential role downstream of TCR signaling by hydrolyzing phosphatidylinositol 4,5-bisphosphate to form inositol 1,4,5-triphosphate and diacylglycerol. *PLCG1* mutation may cause its constitutive activation and augment TCR signalling, thereby contributing AITL development.

TNFRSF21, encoding the death receptor-6 (DR6), was mutated in 1 of the 9 AITLs investigated by WES. The mutation is a frameshift deletion in the death domain, and most likely leads to inactivation of its encoded protein

product. DR6 appears to act as a negative regulator to dampen immunoreceptor-coupled signaling pathways [22, 23], although its molecular function is still elusive. In absence of DR6, CD4+ T cells are hyper-proliferative and show a profound polarization toward a Th2 phenotype in response to TCR stimulation [22, 24, 25]. In light of these findings, *TNFRSF21* inactivation is an attractive pathogenic mechanism in AITL development. In addition to genetic changes, it is pertinent to investigate other potential mechanisms such as epigenetic changes that may inactivate *TNFRSF21* in AITL in future studies.

CCND3 was mutated in 1 of the 9 AITLs investigated by WES, and the mutation generated a premature stop codon, predicting a truncated protein product. Similar nonsense or frameshift mutations have been recently reported in Burkitt lymphoma [26, 27]. These mutations eliminate the cyclin D3 carboxyl terminus that contains a phosphorylation motif, highly conserved among cyclin D3 homologs. This phosphorylation motif is critical for phosphorylation and polyubiquitination of D-type cyclin and thus their proteasome degradation [28]. As expected, these mutations markedly increase cyclin D3 stability and enhance its ability in driving cell proliferation [27].

SAMSN1 was mutated in 1 of the 9 AITLs investigated by WES, and the mutation generated a stop codon upstream of the SH3 domain, thus most likely being a loss of function change. *SAMSN1* is a tumour suppressor gene in multiple myeloma. Germline deletion of *Samsn1* in mice predisposes to monoclonal gammopathy of undetermined significance and multiple myeloma, while in human *SAMSN1* expression is inactivated by promoter methylation [29]. In addition, SAMSN1 is a negative regulator of cell proliferation as shown by *in vitro* studies [30]. Thus, SAMSN1 mutation seen in AITL is highly likely pathogenic.




Figure 3: Distribution of the shortlisted pathogenic mutations in 9 cases of AITL investigated by WES. There is no apparent association among the mutations identified.

Evidence for stepwise acquisition of genetic abnormalities with distinct oncogenic properties

Despite the diverse spectrum of somatic mutations identified in AITL by whole exome and targeted sequencing, there is a small set of genes including *TET2*, *DNMT3A*, *IDH2* and *RHOA*, which are commonly found to be mutated by different studies including the present study [8–11]. Among these, *TET2*, *DNMT3A* and *IDH2* mutations are also found in a range of hematological malignancies with *IDH2* mutation additionally seen in several types of solid tumor, particularly low grade gliomas [31, 32]. Interestingly, *IDH2* mutation in AITL, like glioma, exclusively affects the R172 residue [8, 11, 12, 15, 32], but involves both R140 and R172 residues in acute myeloid leukemia and myelodysplastic syndromes with R140 mutation being more frequent [33, 34]. *TET2* and *DNMT3A* mutation appear to occur at an early stage of hematopoietic cell differentiation as these mutations are also found in non-malignant hematopoietic cells of patients with PTCL as well as normal elderly individuals [9, 35–37]. Their involvement in various malignancies and occurrence in hematopoietic progenitor cells are in keeping with their general role in regulation of DNA methylation, and the observation of an expanded hematopoietic stem cell pool in mice when *Tet2* or *Dnmt3a* is deleted or *Idh2* mutant is expressed in mouse bone marrow cells [38, 39]. Taken together, these findings suggest that *TET2*, *DNMT3A* and *IDH2* mutations are unlikely to have a major role in driving cell differentiation towards the T-cell lineage, thus require cooperating events, which are crucial for the development and biology of T-cells, in the genesis of AITL (Figure 4).

The other frequently mutated gene found by different studies is *RHOA*, which is a small GTPase and

alternates between an active GTP-bound configuration and an inactive GDP-bound state. The *RHOA* Gly17Val mutant does not bind GTP and inhibits the wild-type *RHOA* function by sequestering the *RHOA* guanine nucleotide exchange factors [8, 9]. *RhoA* has been shown to play important roles in the development and differentiation of thymocytes as well as in the biology of mature T-cells including TH2 cell differentiation [40, 41]. Although the precise molecular mechanisms of *RHOA* in T-cell biology remain to be investigated, it is pertinent to speculate that *RHOA* mutation may occur later than those in the aforementioned DNA methylation regulators, and its functional deregulation by mutation may promote T-cell differentiation and malignant transformation (Figure 4). In line with this notion, a recent study by RNA sequencing has identified a novel *CTLA4-CD28* fusion in AITL and other T-cell lymphoma subtypes [42]. The fusion combines the extracellular domain of *CTLA4* with the cytoplasmic region of *CD28*, thus converting inhibitory signals into stimulatory signals for T-cell activation [42]. Interestingly, there is a considerable overlap between *CTLA4-CD28* fusion and *RHOA* mutation in AITL [42], suggesting possible oncogenic cooperation between the two events. In addition, *CD28* is frequently activated by mutation in AITL with the D124 mutant showing increased affinity for ligand *CD86* and the T195 mutant displaying increased affinity for intracellular adaptor proteins *GRB2* and *GADS/GRAP2* [14]. In view the established role of *RHOA* and *CD28* in T-cell biology, *RHOA* mutation and *CTLA4-CD28* fusion/*CD28* mutation could be regarded as T-cell lineage impact events, i.e. determining the phenotype of transformed cells. In this context, the present study identifies further genetic changes, namely *PLCG1* and *TNFRSF21* mutation, of this category in AITL (Figure 4).




Figure 4: The proposed model of multistage development in AITL. Mutations in DNA methylation regulators namely *TET2*, *DNMT3A* and *IDH2* are early events, with *TET2* and *DNMT3A* mutation occurring in hematopoietic stem cells. These genetic events enhance the self-renewal of hematopoietic stem cells, and do not have any major impact on cell lineage specific differentiation, thus are found in a variety of haematological malignancies. Mutation in *RHOA*, *PLCG1*, *TNFRSF21*, *CD28* and the *CTLA4-CD28* and *ITK-SYK* fusion occurs late, and these genetic events affect proteins critical to T-cell biology, thus most likely promote T-cell differentiation as well as malignant transformation, consequently generating the malignant phenotype.

MATERIALS AND METHODS

Patients samples

High molecular weight (HMW) DNA samples were extracted from fresh frozen specimens of 9 AITL from Department of Pathology, Chi-Mei Foundation Hospital, Taiwan ($n = 6$), and Department of Cellular Pathology, Southampton University Hospitals National Health Service Trust, Southampton, U.K. ($n = 3$) (Supplementary Table 3). The lymphoma diagnosis was established according to the 2008 WHO classification of tumours of haematopoietic and lymphoid tissues. In 6 cases where indicated, germline DNA were extracted from non-neoplastic formalin-fixed paraffin-embedded (FFPE) tissues or peripheral blood samples not involved by lymphoma, but sufficient amount of DNA was only available in 1 case for WES (Supplementary Table 3). Local ethical guidelines were followed for the use of archival tissues for research with the approval of the ethics committees of the involved institutions.

Whole exome sequencing and somatic variant calling

These were carried out by the Wellcome Trust Sanger Institute. WES was successfully performed on 9 AITL DNA samples and 1 matched germline DNA sample as described previously [43]. Genomic libraries were prepared using the Illumina Paired End Sample Prep Kit, and target enrichment was performed using the Agilent SureSelect Human All Exon 50Mb kit. Each exome was sequenced using a 75bp paired-end protocol on an Illumina HiSeq platform. Sequencing reads were aligned to the hg19 reference genome using the BWA algorithm on default settings.

Variants were called using the Caveman and Pindel algorithms and subjected to a series of post processing filters to remove SNPs presented in germline DNA from this study, known SNPs ($\geq 1\%$) in databases and in both east Asian and European populations of the 1000 genomes project. In addition, the variants discovered were checked against the COSMIC database to identify potential somatic and pathogenic changes. Finally, the variants discovered were further analyzed with 7 mutation functional prediction programs including SIFT, Polyphen-2 HDIV, Polyphen-2 DVAR, Mutation Assessor, FATHMM, GERP++ and SiPhy-29, and those predicted to be damaging by 5 or more programs were included in the final variant list.

Somatic variant validation by PCR and sanger sequencing

Where indicated, novel variants identified by WES were confirmed by PCR and Sanger sequencing using the BigDye Terminator 3.1 System (Applied Biosystems, UK)

on an ABI 3730 instrument (Applied Biosystems, UK), and their somatic nature was ascertained by analysis of germline DNA.

ACKNOWLEDGMENTS AND FUNDING

The research was supported by grants from Kay Kendall Leukaemia Fund (KKL582), and Bloodwise, U.K. (13006). SZ was supported by a scholarship from the Master Hsingyun Cultural and Education Foundation. We thank Wenhan Deng for DNA preparation in some of the cases used in this study.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

REFERENCES

1. Gaulard P, de Leval L. Follicular helper T cells: implications in neoplastic hematopathology. *Semin Diagn Pathol.* 2011; 28:202–213.
2. Ahearne MJ, Allchin RL, Fox CP, Wagner SD. Follicular helper T-cells: expanding roles in T-cell lymphoma and targets for treatment. *Br J Haematol.* 2014; 166:326–335.
3. Streubel B, Vinatzer U, Willheim M, Raderer M, Chott A. Novel t(5;9)(q33;q22) fuses ITK to SYK in unspecified peripheral T-cell lymphoma. *Leukemia.* 2006; 20:313–318.
4. Huang Y, Moreau A, Dupuis J, Streubel B, Petit B, Le Gouill S, Martin-Garcia N, Copie-Bergman C, Gaillard F, Qubaja M, Fabiani B, Roncador G, Haioun C, et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. *Am J Surg Pathol.* 2009; 33:682–690.
5. Attygalle AD, Feldman AL, Dogan A. ITK/SYK translocation in angioimmunoblastic T-cell lymphoma. *Am J Surg Pathol.* 2013; 37:1456–1457.
6. Pechloff K, Holch J, Ferch U, Schweneker M, Brunner K, Kremer M, Sparwasser T, Quintanilla-Martinez L, Zimmer-Strobl U, Streubel B, Gewies A, Peschel C, Ruland J. The fusion kinase ITK-SYK mimics a T cell receptor signal and drives oncogenesis in conditional mouse models of peripheral T cell lymphoma. *J Exp Med.* 2010; 207:1031–1044.
7. Dierks C, Adrian F, Fisch P, Ma H, Maurer H, Herchenbach D, Forster CU, Sprissler C, Liu G, Rottmann S, Guo GR, Katja Z, Veelken H, et al. The ITK-SYK fusion oncogene induces a T-cell lymphoproliferative disease in mice mimicking human disease. *Cancer Res.* 2010; 70:6193–6204.
8. Palomero T, Couronne L, Khiabanian H, Kim MY, Ambesi-Impiombato A, Perez-Garcia A, Carpenter Z, Abate F, Allegretta M, Haydu JE, Jiang X, Lossos IS, Nicolas C, et al. Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. *Nat Genet.* 2014; 46:166–170.

9. Sakata-Yanagimoto M, Enami T, Yoshida K, Shiraishi Y, Ishii R, Miyake Y, Muto H, Tsuyama N, Sato-Otsubo A, Okuno Y, Sakata S, Kamada Y, Nakamoto-Matsubara R, et al. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma. *Nat Genet.* 2014; 46:171–175.
10. Yoo HY, Sung MK, Lee SH, Kim S, Lee H, Park S, Kim SC, Lee B, Rho K, Lee JE, Cho KH, Kim W, Ju H, et al. A recurrent inactivating mutation in RHOA GTPase in angioimmunoblastic T cell lymphoma. *Nat Genet.* 2014; 46:371–375.
11. Odejide O, Weigert O, Lane AA, Toscano D, Lunning MA, Kopp N, Kim S, van Bodegom D, Bolla S, Schatz JH, Teruya-Feldstein J, Hochberg E, Louissaint A, et al. A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. *Blood.* 2014; 123:1293–1296.
12. Cairns RA, Iqbal J, Lemonnier F, Kucuk C, de Leval L, Jais JP, Parrens M, Martin A, Xerri L, Brousset P, Chan LC, Chan WC, Gaulard P, et al. IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. *Blood.* 2012; 119:1901–1903.
13. Lemonnier F, Couronne L, Parrens M, Jais JP, Travert M, Lamant L, Tournillac O, Rousset T, Fabiani B, Cairns RA, Mak T, Bastard C, Bernard OA, et al. Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. *Blood.* 2012; 120:1466–1469.
14. Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, Simone PD, Zhang W, Gong Q, Wang C, Cannon A, Heavican T, Mottok A, et al. Recurrent activating mutations of CD28 in peripheral T-cell lymphomas. *Leukemia.* 2016; 30:1062–1070.
15. Wang C, McKeithan TW, Gong Q, Zhang W, Bouska A, Rosenwald A, Gascoyne RD, Wu X, Wang J, Muhammad Z, Jiang B, Rohr J, Cannon A, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T-cell lymphoma. *Blood.* 2015; 126:1741–1752.
16. Vaque JP, Gomez-Lopez G, Monsalvez V, Varela I, Martinez N, Perez C, Dominguez O, Grana O, Rodriguez-Peralto JL, Rodriguez-Pinilla SM, Gonzalez-Vela C, Rubio-Camarillo M, Martin-Sanchez E, et al. PLCG1 mutations in cutaneous T-cell lymphomas. *Blood.* 2014; 123:2034–2043.
17. Manso R, Rodriguez-Pinilla SM, Gonzalez-Rincon J, Gomez S, Monsalvo S, Llamas P, Rojo F, Perez-Callejo D, Cereceda L, Limeres MA, Maeso C, Ferrando L, Perez-Seoane C, et al. Recurrent presence of the PLCG1 S345F mutation in nodal peripheral T-cell lymphomas. *Haematologica.* 2015; 100:e25–e27.
18. Bunney TD, Esposito D, Mas-Droux C, Lamber E, Baxendale RW, Martins M, Cole A, Svergun D, Driscoll PC, Katan M. Structural and functional integration of the PLCgamma interaction domains critical for regulatory mechanisms and signaling deregulation. *Structure.* 2012; 20:2062–2075.
19. Timsah Z, Ahmed Z, Lin CC, Melo FA, Stagg LJ, Leonard PG, Jeyabal P, Berrout J, O'Neil RG, Bogdanov M, Ladbury JE. Competition between Grb2 and Plcgamma1 for FGFR2 regulates basal phospholipase activity and invasion. *Nat Struct Mol Biol.* 2014; 21:180–188.
20. Behjati S, Tarpey PS, Sheldon H, Martincorena I, Van Loo P, Gundem G, Wedge DC, Ramakrishna M, Cooke SL, Pillay N, Vollen HK, Papaemmanuil E, Koss H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. *Nat Genet.* 2014; 46:376–379.
21. Vallois D, Dobay MP, Morin RD, Lemonnier F, Missiaglia E, Juilland M, Iwaszkiewicz J, Fataccioli V, Bisig B, Roberti A, Grewal J, Bruneau J, Fabiani B, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell-derived lymphomas. *Blood.* 2016; 128:1490–1502.
22. Benschop R, Wei T, Na S. Tumor necrosis factor receptor superfamily member 21. TNFR-related death receptor-6, DR6. *Adv Exp Med Biol.* 2009; 647:186–194.
23. Klima M, Brouckova A, Koc M, Andera L. T-cell activation triggers death receptor-6 expression in a NF-kappaB and NF-AT dependent manner. *Mol Immunol.* 2011; 48:1439–1447.
24. Liu J, Na S, Glasebrook A, Fox N, Solenberg PJ, Zhang Q, Song HY, Yang DD. Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice. *Immunity.* 2001; 15:23–34.
25. Zhao H, Yan M, Wang H, Erickson S, Grewal IS, Dixit VM. Impaired c-Jun amino terminal kinase activity and T cell differentiation in death receptor 6-deficient mice. *J Exp Med.* 2001; 194:1441–1448.
26. Richter J, Schlesner M, Hoffmann S, Kreuz M, Leich E, Burkhardt B, Rosolowski M, Ammerpohl O, Wagener R, Bernhart SH, Lenze D, Szczepanowski M, Paulsen M, et al. Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing. *Nat Genet.* 2012; 44:1316–1320.
27. Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, Wright G, Shaffer AL, Hodson DJ, Buras E, Liu X, Powell J, Yang Y, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. *Nature.* 2012; 490:116–120.
28. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. *Genes Dev.* 1997; 11:957–972.
29. Noll JE, Hewett DR, Williams SA, Vandyke K, Kok C, To LB, Zannettino AC. SAMS1 is a tumor suppressor gene in multiple myeloma. *Neoplasia.* 2014; 16:572–585.
30. Amend SR, Wilson WC, Chu L, Lu L, Liu P, Serie D, Su X, Xu Y, Wang D, Gramolini A, Wen XY, O'Neal J, Hurchla M, et al. Whole Genome Sequence of Multiple Myeloma-Prone C57BL/KaLwRij Mouse Strain Suggests the Origin of Disease Involves Multiple Cell Types. *PLoS One.* 2015; 10:e0127828.

31. Hamidi T, Singh AK, Chen T. Genetic alterations of DNA methylation machinery in human diseases. *Epigenomics*. 2015; 7:247–265.
32. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, et al. IDH1 and IDH2 mutations in gliomas. *N Engl J Med*. 2009; 360:765–773.
33. Abbas S, Lugthart S, Kavelaars FG, Schelen A, Koenders JE, Zeilemaker A, van Putten WJ, Rijneveld AW, Lowenberg B, Valk PJ. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. *Blood*. 2010; 116:2122–2126.
34. Kosmider O, Gelsi-Boyer V, Slama L, Dreyfus F, Beyne-Rauzy O, Quesnel B, Hunault-Berger M, Slama B, Vey N, Lacombe C, Solary E, Birnbaum D, Bernard OA, et al. Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. *Leukemia*. 2010; 24:1094–1096.
35. Couronne L, Bastard C, Bernard OA. TET2 and DNMT3A mutations in human T-cell lymphoma. *N Engl J Med*. 2012; 366:95–96.
36. Quivoron C, Couronne L, Della V, V, Lopez CK, Plo I, Wagner-Ballon O, Do CM, Delhommeau F, Arnulf B, Stern MH, Godley L, Opolon P, et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. *Cancer Cell*. 2011; 20:25–38.
37. Xie M, Lu C, Wang J, McLellan MD, Johnson KJ, Wendl MC, McMichael JF, Schmidt HK, Yellapantula V, Miller CA, Ozenberger BA, Welch JS, Link DC, et al. Age-related mutations associated with clonal hematopoietic expansion and malignancies. *Nat Med*. 2014; 20:1472–1478.
38. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. The role of mutations in epigenetic regulators in myeloid malignancies. *Nat Rev Cancer*. 2012; 12:599–612.
39. Kats LM, Reschke M, Taulli R, Pozdnyakova O, Burgess K, Bhargava P, Straley K, Karnik R, Meissner A, Small D, Su SM, Yen K, Zhang J, et al. Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance. *Cell Stem Cell*. 2014; 14:329–341.
40. Zhang S, Konstantinidis DG, Yang JQ, Mizukawa B, Kalim K, Lang RA, Kalfa TA, Zheng Y, Guo F. Gene targeting RhoA reveals its essential role in coordinating mitochondrial function and thymocyte development. *J Immunol*. 2014; 193:5973–5982.
41. Yang JQ, Kalim KW, Li Y, Zhang S, Hinge A, Filippi MD, Zheng Y, Guo F. RhoA orchestrates glycolysis for TH2 cell differentiation and allergic airway inflammation. *J Allergy Clin Immunol*. 2016; 137:231–245.
42. Yoo HY, Kim P, Kim WS, Lee SH, Kim S, Kang SY, Jang HY, Lee JE, Kim J, Kim SJ, Ko YH, Lee S. Frequent CTLA4-CD28 gene fusion in diverse types of T cell lymphoma. *Haematologica*. 2016.
43. Clipson A, Wang M, de Leval L, Ashton-Key M, Wotherspoon A, Vassiliou G, Bolli N, Grove C, Moody S, Escudero-Ibarz L, Gundem G, Brugger K, Xue X, et al. KLF2 mutation is the most frequent somatic change in splenic marginal zone lymphoma and identifies a subset with distinct genotype. *Leukemia*. 2015; 29:1177–1185.